Red Light Therapy for AMD

Red Light Therapy and Age-Related Macular Degeneration: What the Evidence Actually Shows

Age-related macular degeneration (AMD) is the leading cause of vision loss in people over 60 in the developed world, and it's a diagnosis that understandably sends people searching for anything that might slow it down. In the last few years, "red light therapy" — more precisely known in medicine as photobiomodulation (PBM) — has moved from a fringe idea to a genuine, FDA-authorized treatment option for a specific stage of dry AMD. But there's an important gap between the clinical device your retina specialist might use and the red light panels sold online for skin and wellness, and mixing the two up matters.

Here's what the research actually says.

What is photobiomodulation, exactly?

Photobiomodulation uses low-level, specific wavelengths of red and near-infrared light — not the broad-spectrum red light panels marketed for skincare — to stimulate the mitochondria inside retinal cells. The theory is that AMD involves declining mitochondrial energy production in the retinal pigment epithelium (the layer of cells that supports the light-sensing photoreceptors), and that certain wavelengths of light can boost cellular energy output (ATP production) and reduce inflammation and oxidative stress in that tissue. It's the same underlying biological mechanism explored in PBM for wound healing and musculoskeletal pain, applied to the eye.

This is not the same thing as shining a red light bulb at your face. Clinical PBM for AMD uses a calibrated combination of wavelengths (typically in the yellow, red, and near-infrared range, around 590nm, 660nm, and 850nm), delivered at a specific intensity and duration, administered in-office.

The device that changed the conversation: Valeda

The most researched PBM system for AMD is the Valeda Light Delivery System, made by LumiThera. In November 2024, the FDA granted it de novo authorization — the first and, so far, only FDA-authorized light-based treatment for dry AMD. It's intended for people with intermediate dry AMD who haven't yet progressed to geographic atrophy (the advanced, vision-threatening form of dry AMD).

The authorization was based on the LIGHTSITE III trial, a randomized, sham-controlled study that found:

At 13 months, roughly 55% of treated eyes gained at least 5 letters of visual acuity on an eye chart, with no meaningful gains in the sham (placebo) group.
Treated eyes showed no increase in drusen (the fatty deposits under the retina that are a hallmark of AMD), while drusen worsened in untreated eyes.
Extended to 24 months, the trial reported that repeated treatment maintained the visual acuity gains and showed a statistically significant reduction in the rate of conversion to geographic atrophy among intermediate AMD patients.
A further extension study (LIGHTSITE IIIB), reported in May 2025, showed the vision improvements held up over a longer follow-up period with continued treatment.

Treatment isn't a one-time fix: it involves an in-office regimen of multiple short sessions, repeated periodically, to maintain the benefit — more akin to a maintenance therapy than a cure.

A more cautious, independent data point

Not every study has been as encouraging. The independent PBM4AMD study, published in Eye in 2024, followed 38 patients with early or intermediate AMD through nine PBM sessions using the same type of device. It found real but temporary improvements: visual acuity and drusen volume both improved at one and three months, but the effect faded by six months, with drusen volume partially rebounding. Two patients in the study developed macular neovascularization (an abnormal blood vessel growth associated with progression to wet AMD), though researchers attributed this to those patients' pre-existing risk factors rather than the treatment itself.

The takeaway from independent researchers has been consistent: PBM shows real, measurable biological effects, but questions remain about how durable those effects are, which patients benefit most, and whether ongoing maintenance sessions are truly necessary indefinitely. A larger trial, EUROLIGHT, enrolling 500–1,000 patients across all stages of AMD over three years, is now underway and may give regulators like the UK's NICE enough data to make broader recommendations.

What this means if you're considering it

A few practical points worth understanding before pursuing PBM for AMD:

It's for dry AMD, not wet AMD. The approved use case is intermediate dry AMD. It is not a treatment for wet (neovascular) AMD, which is managed with anti-VEGF injections, and it's not indicated for advanced geographic atrophy.

Clinical devices require professional supervision. Valeda and similar systems are administered in an eye care provider's office under a specific, tested protocol — not something replicated by an at-home red light panel. The wavelengths, dosing, and treatment intervals used in the trials were precisely calibrated, and there's no clinical evidence that generic consumer red light devices marketed for skin, hair, or general wellness produce the same retinal effects. Some ophthalmologists have also raised general caution about pointing unregulated, high-intensity light devices directly at the eyes, given the retina's sensitivity to light-induced damage.

It's a maintenance therapy, not a cure. Benefits shown in trials required repeated sessions over time; discontinuing treatment isn't well studied but is not associated with retaining large permanent gains.

Talk to a retina specialist. Whether PBM makes sense depends on which stage of AMD you have, other eye conditions, and how you weigh a still-evolving evidence base against the time and cost of ongoing in-office visits.

The bottom line

Red light therapy for AMD has gone from a plausible-sounding idea to a real, FDA-authorized treatment backed by randomized trial data — a rare thing in the world of light-based wellness claims. The evidence for intermediate dry AMD is genuinely encouraging, particularly around slowing progression to geographic atrophy. At the same time, independent research urges some caution about how long the benefits last and for whom the treatment works best. If you or a family member has AMD, the right first step isn't a consumer red light panel — it's a conversation with a retina specialist about whether your stage of disease and overall eye health make you a good candidate for a clinically supervised PBM protocol.

If you consider this treatment we highly recommend Bed Light & Beyond in London (41 Brecknock Road).The goal was to make this cellular recovery and wellness AMD treatment affordable and accessible to people on lower incomes rather than just a luxury reserved for the wealthy.